Kristmundsdottir F, David T J
J R Soc Med. 1987 Jan;80(1):9-12. doi: 10.1177/014107688708000106.
Growth was studied in 89 children with atopic eczema aged 1-16 years. Nine (10%) had a standing height below the 3rd centile. Both boys and girls had significantly reduced sitting height but normal subischial leg length, and both sexes had significantly delayed skeletal maturity scores. Impaired growth was particularly associated with widespread eczema, but also with the presence of asthma and the potency of topical corticosteroid. Six of the 15 patients with a corrected height centile below the 10th centile had been receiving potent (British National Formulary category I or II) topical corticosteroids. This study suggests that impaired linear growth is a feature of atopic eczema. While the causes of the growth impairment are unclear, there is a need for caution in the use of potent topical corticosteroids in children.
对89名年龄在1至16岁的特应性皮炎患儿的生长情况进行了研究。其中9名(10%)患儿的身高低于第3百分位数。男孩和女孩的坐高均显著降低,但坐骨下腿长正常,且两性的骨骼成熟度评分均显著延迟。生长发育受损尤其与广泛的湿疹有关,但也与哮喘的存在以及外用糖皮质激素的效力有关。在15名身高百分位数校正后低于第10百分位数的患者中,有6名一直在接受强效(英国国家处方集I类或II类)外用糖皮质激素治疗。这项研究表明,线性生长受损是特应性皮炎的一个特征。虽然生长受损的原因尚不清楚,但在儿童中使用强效外用糖皮质激素时需要谨慎。